



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

In re Application of:) Art Unit: 1645
GRAVERSEN, et al.) Examiner:
Serial No.: 09/987,107) Washington, D.C.
Filed: November 13, 2001) July 9, 2002
For: APOLIPOPROTEIN ANALOGUES) Docket No.: GRAVERSEN=1A
Confirmation No.: 6444

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

S i r :

IN THE CLAIMS

Please amend claims 2, 10, 14, 32, 33, 36, 37, 39, 43, 50, 53, 58, 62, 64, 68, 70, 71, 72, 73, 81 and 82, to read:

1
A 2 (amended). The composition of claim 1, further comprising a spacer between the apo-A component and X, wherein the spacer comprises a spacer peptide comprising at least two amino acids.

2
A 10 (amended). The composition of claim 7, wherein the protein comprises at least one protein selected from the group comprising albumin, the serine protease fragment of plasminogen or another serine protease engineered to be inactive by disruption of the catalytic triad, and the constant region of the heavy chain of immunoglobulins.

3
A 14 (amended). The composition of claim 7, wherein the peptide constituting the component X comprises at least two amino acids.

32 (amended). The composition of claim 1, having a half-life at least 2 times the half-life of native Apo A-I, A-II or A-IV.

4
A 33 (amended). The composition of claim 1, capable of binding to a receptor selected from the group consisting of cubilin, Scavenger receptor class B, type 1 (SR-B1), ATP-binding cassette 1 (ABC1), Lecithin:cholesterol acyltransferase (LCAT), Cholesteryl-ester transfer protein (CETP), and Phospholipid transfer protein (PLTP).

5
A 36 (amended). The composition according to claim 1, said

PRE AMEND 1A
AJ
P# 7
3-17-03